Abstract
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study, was conducted to examine reactogenicity within the first 2 days after vaccination with either a protein-based vaccine (NVX-CoV2373) or an mRNA vaccine (BNT162b2 or mRNA-1273) in individuals who previously completed a primary series. Propensity score adjustments were conducted to address potential confounding. The analysis included 1130 participants who received a post–primary series dose of NVX-CoV2373 (n = 303) or an mRNA vaccine (n = 827) during the study period. Within the first 2 days after vaccination, solicited systemic reactogenicity events (adjusted) were reported in 60.5% of participants who received NVX-CoV2373 compared with 84.3% of participants who received an mRNA vaccine; moreover, 33.9% and 61.4%, respectively, reported ≥3 systemic reactogenicity symptoms. The adjusted mean (95% CI) number of systemic symptoms was 1.8 (1.6–2.0) and 3.2 (3.0–3.4), respectively. Local reactogenicity events (adjusted) were reported in 73.4% and 91.7% of participants who received NVX-CoV2373 and mRNA vaccines, respectively; the adjusted mean (95% CI) number of local symptoms was 1.5 (1.33–1.61) and 2.4 (2.31–2.52), respectively. These results support the use of adjuvanted, protein-based NVX-CoV2373 as an immunization option with low reactogenicity.
Competing Interest Statement
MDR, AMM, ST, HB, and MM are employees of Novavax, Inc. and may hold stock in Novavax, Inc. KH, RZ, SO, DO, and LJ are employees of RTI Health Solutions, an independent research consultancy that received funding under a research contract with Novavax, Inc. to conduct this study. The funder participated in the design and interpretation of the data and the writing of this manuscript but had no role in the collection or analysis of the data or in the decision to publish these results.
Funding Statement
This research was funded by Novavax, Inc., and the APC was funded by Novavax, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Advarra (Approval notice MOD01579170, approved 24 February 2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
mrousculp{at}novavax.com (M.D.R.);
amarchese{at}novavax.com (A.M.M.);
mmontazeri{at}novavax.com (M.M.);
hbeyhaghi{at}novavax.com (H.B.);
stoback{at}novavax.com (S.T.)
khollis{at}rti.org (K.H.);
rziemiecki{at}rti.org (R.Z.);
dodom{at}rti.org (D.O.);
sodak{at}rti.org (S.O.);
gibson{at}rti.org (L.J.)
Data Availability
Data are available on request due to privacy restrictions. The data presented in this study are available in aggregate form on request to the corresponding author. The data are not publicly available due to privacy requirements.
